Inflammatory Bowel Disease

Disease State Hub

FDA Alerts

FDA alert

First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease

05/25/2023

Jessica Ganga

After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.

05/25/2023

Research Summaries

Research Summary

Research Summary

Early vs Delayed Advanced Therapy Among Adult Patients With Moderate Ulcerative Colitis

03/30/2024

Anthony Calabro, MA

Researchers compared the health outcomes of adult patients with moderate ulcerative colitis and early advanced therapy initiation with those who delayed their advanced treatment initiation.

03/30/2024

FDA alert

First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease

05/25/2023

Jessica Ganga

After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.

05/25/2023

treatment initiation

Early Treatment Initiation Improves Outcomes in Patients With Crohn Disease

12/29/2022

Researchers examined the impact that time-to-initiation of biologic treatment had on the risk of adverse outcomes among individuals with Crohn disease.

12/29/2022

Conference Coverage

Upadacitinib Superior to Placebo For Moderately to Severely Active Crohn Disease

10/31/2022

A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.

10/31/2022

Conference Coverage

Risankizumab Significantly Reduces, Resolves Symptoms of Crohn Disease

10/28/2022

The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022. ...

10/28/2022

September 2024

Current Issue

September 2024

Volume 64

Issue 9